Fundz
Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every contract, funding round, exec hire, and M&A move on Amyris — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plansBook a 15-min walkthrough
Watch the 2-minute tour · with sound

Amyris Awarded Agreement from BioMaP-Consortium for $12.3 million to Develop Critical Medicines

Oct 03, 2024over 1 year ago

Contract Type

agreement

EmeryvilleManufacturingBiotechnology

Description

Amyris has been awarded an agreement through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-C) for $12.3 million from the Administration for Strategic Preparedness and Response's (ASPR) Center for Industrial Base Management and Supply Chain (IBMSC) to advance innovative pharmaceutical manufacturing in the United States. Amyris aims to develop up to three small molecule drugs over the next two years to address the FDA drug shortage list.

Company Information

Company

Amyris

Location

5885 HOLLIS STREET, SUITE 100

Emeryville, California, United States

About

Amyris is a global leader in renewable biological chemistry, powered by decades of experience and a world-class technology and manufacturing platform. With a proven track record of commercially successful ingredients and building blocks, Amyris has pioneered the use of living systems to convert abundant plant-based sugars into high-performance molecules. Our innovative fermentation-based products serve diverse industries including beauty, advanced materials, food, flavors & fragrances, and beyond, and are found in tens of thousands of products worldwide.

Predictive Intelligence
Strategic

ML-powered predictions for Amyris's next move

Learn about Strategic plan

Related People

Suggested for you

Sign in to view contact details

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months